PhageLab

Private

SantiagoHealthcare & Life Scienceshttps://phage-lab.com/

Last Round

Series A

Jan 23, 2024

Total Funding Raised

$44.5M

Company Overview

PhageLab is a biotechnology company that develops precision bacteriophage treatments to reduce the overuse of antibiotics and control bacteria in the livestock industry.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Drug Discovery, Medical AI

Business Model

B2B

Customer Profile

Services & Consulting, Subscription SaaS

AI Layer

Application

Keywords

bacteriophage solution for animal productionAI-powered microbial bioinformatics platformcustomized phage cocktail for livestockantibiotic alternative for livestockmultidrug-resistant bacteria controlSalmonella control in poultryE. coli control in swinebacteriophage therapy for animal healthlivestock pathogen diagnostic serviceprecision medicine for animal healthClostridium perfringens control in swineanimal health biotechnology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

PhageLab Comparables

Compare PhageLab with similar companies based on industry and business-model similarity.

PhageLab comparables — related companies by embedding similarity
Company	Similarity	Market Cap

View Full Comparables Set

Access detailed peer comparisons, similarity scores, and market data.

PhageLab Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Series A	Jan 23, 2024
Series A	May 23, 2022

View all Funding Rounds

Key People

Founding team and executive leadership

Pablo Cifuentes Palma

Chief Operating Officer

Executive Team

PhageLab Investors

Notable investors and investment history

PhageLab investors
Investor	Rounds
Nazca	Series A
Humboldt Fund	Series A
Collaborative Fund	Series A
Waterlemon	Series A
The Yield Lab	Convertible Debt
Kaszek	Series A, Convertible Debt

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Jan 23, 2024
Raised $11M with participation from Collaborative Fund and Nazca.
May 23, 2022
$30M round led by Humboldt Fund and Kaszek.

View all signals

PhageLab Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

PhageLab Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about PhageLab's valuation, stock price, and market status.

Firmographic Details

HeadquartersSantiago

Employee Range74

Year Founded2010

Last FundingJan 23, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.